Clinical Trials Browser

Not yet recruiting × Lymphoma, T-Cell, Peripheral × Clear all

NCT07192471 2026-04-20

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

Phase 1 Not yet recruiting

DermatologicLymphoid

Immune System Diseases, Lymphoma, Mycosis Fungoides, Neoplasms, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT07535762 2026-04-17

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma

Phase 2 Not yet recruiting

Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT07180771 2026-01-28

A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.

Phase 2 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT07288814 2025-12-17

Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

Phase 1/2 Not yet recruiting

Recurrence, Lymphoma, T-Cell, Peripheral

NCT07279584 2025-12-12

Golidocitinib Combined With GemOx in RR PTCL

Phase 2 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT07209163 2025-10-06

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

Phase 1/2 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT07081607 2025-07-23

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

Phase 2 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT06385522 2025-07-08

A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System

Phase 1 Not yet recruiting

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT07032532 2025-06-26

Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)

Phase 2 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT06963632 2025-05-09

JOYCE

Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT06757387 2025-01-03

Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma

Phase 1/2 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT06712173 2024-12-02

Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

Phase 1 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT06702605 2024-11-25

To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

Phase 2 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT06671717 2024-11-06

Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma

Phase NA Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT06548347 2024-08-12

A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma

Phase 2/3 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT05923502 2023-10-23

(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)

Not yet recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, B-Cell, Marginal Zone

NCT05900089 2023-06-12

Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma

Phase 1 Not yet recruiting

Lymphoma, T-Cell, Peripheral